It is very nice to visit Lambda facility and thanks to warm welcome provided by all the teams. I can easily say one of the best CRO I ever visited. People here are wonderful and doing great job

Reputed Client of Israel

Awesome hospitality & fantastic office. All the best!

Reputed Client of Japan

Excellent hospitality and cooperation received throughout the audit. People are knowledgeable and extremely transparent. Looking for long time relation

Reputed Client of Asia

Facility is too good to conduct the BABE studies and adherence to protocol and quality assurance in conducting studies are meeting sponsor expectations and requirements.

Reputed Client of India

Facility is good, people r trained well and know the subject on which they r working. All the best.

Reputed Client of USA

Highly innovative and advanced research centre that possess bright future for the development of the country.

Reputed International Government Body

It is one of the best facility in India for BA/BE

Reputed Regulatory Authority

Lambda is a very professional CRO. All the staff here are experienced and very knowledgeable. I'm grateful for their accommodations and hospitality. The future, if we want to carry out BE study, we will ask Lambda help again.

Reputed Client of Europe

It was a really pleasant meeting with the PV department, and I am looking forward to the next visit.

Reputed Client of Europe

Amazing and best CRO I ever seen

Reputed Client of China



Home / Blog

Common Considerations for Submitting Pharmacokinetic (PK) Values in CDISC Format

02 Feb 2018

Any human clinical trial generates pharmacokinetic (PK) data, and those are the basic raw data for statistical analysis where BA/BE parameters are the primary endpoints. PK data are also used to determine dosing regimen, dose tolerability, and effective dosing interval.

Here, we discuss some of the challenges associated with representation of the collected concentration data and the calculation of PK parameters followed by conversion in the Clinical Data Interchange Standards Consortium (CDISC) compliant format.

CDISC Background – CDISC is a global organization that develops standards to support the acquisition, tabulation, and submission of clinical data. The mission of CDISC is ‘to develop independent data standards that enable informality for medical research’. More information is available at www.cdisc.org

SDTM Background – The Study Data Tabulation Model (STDM) is a broadly used CDISC standard to submit clinical data in a well organized format. SDTM Implementation Guide (SDTMIG) describes mainly two SDTM domains for PK representing pharmacokinetic concentrations (PC) and pharmacokinetic parameters (PP) datasets; additionally Related Records (RELREC) domain is used for the presentation of the relationship between PC and PP domains. It is also important to incorporate CDISC controlled terminology for PK domains.

PC domain is used for the tabulation of all concentration results for all possible samples (plasma, urine) and has a structure like one record per subject per dosing per drug per time (date and time); therefore in PC domain, subject profiles are represented across multiple records. The PC domain is the base for pharmacokinetic analysis, and can be used for the calculation of parameters like Cmax, Tmax, AUC, etc. which can be further submitted in the PP domain.

Relating PC and PP Records – Once the SDTM datasets are ready, there is one more important thing to do, while submitting the PK data in CDISC format, and that is linking all derived PP records back to the original PC observations. Creation of RELREC is the primary practice to establish relation between PC and PP domains. Basic concept of RELREC is that the related records from each domain (PC & PP) are presented in nearby rows using SDTM standard identifier variables (IDVAR, IDVARVAL, and RELID). RELID is used to uniquely identify records within the dataset.

Lambda Offering
Lambda Therapeutic Research has rich experience in PK analysis and creation of CDISC compliant datasets for regulatory submissions. Recently, we also helped our sponsor (A pharmaceutical client for NDA submission) to re-submit their legacy data in CDISC format to FDA in response to a regulatory query.

Looking for a Globally Proven Research Partner?

Contact Us